Compare TRI & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRI | ZTS |
|---|---|---|
| Founded | 1851 | 1952 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.2B | 49.7B |
| IPO Year | 2002 | 2012 |
| Metric | TRI | ZTS |
|---|---|---|
| Price | $95.22 | $112.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $154.58 | $154.18 |
| AVG Volume (30 Days) | 1.5M | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.62% | 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 6.02 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $8.90 | $5.63 |
| Revenue Next Year | $7.89 | $4.77 |
| P/E Ratio | $25.72 | ★ $18.71 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $79.71 | $112.10 |
| 52 Week High | $218.40 | $172.23 |
| Indicator | TRI | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 37.99 |
| Support Level | $86.48 | N/A |
| Resistance Level | $98.22 | $129.28 |
| Average True Range (ATR) | 4.19 | 2.79 |
| MACD | 0.76 | -0.58 |
| Stochastic Oscillator | 50.90 | 11.93 |
Thomson Reuters is a leading global provider of business information services, delivering trusted data, technology, and expertise to professionals across legal, tax, accounting, risk, compliance, and the news and media sectors. Headquartered in Toronto, Canada, the company combines deep domain knowledge with data and software solutions to help clients make informed decisions, manage complexity, and drive efficiency. Thomson Reuters serves legal and accounting/tax professionals, corporations, and governments worldwide, but around 75% of revenue is generated in the US. The company is known for flagship products such as Westlaw, UltraTax CS, and Reuters News.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.